

CAP TODAY

PATHOLOGY ♦ LABORATORY MEDICINE ♦ LABORATORY MANAGEMENT

SS18-SSX2 fusion transcript in the diagnosis of a poorly differentiated synovial sarcoma

CAPTODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing's important role in diagnosis, prognosis, and treatment. The following report comes

from Penn State Milton S. Hershey Medical Center and Penn State College of Medicine. If you would like to submit a case report, please send an email to the AMP at amp@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.



Erik R. Washburn, MD
Elizabeth E. Fraunhoffer, MD
Rina Kansal, MD

Mesenchymal neoplasms are typically characterized by gene fusions that occur due to chromosomal translocations, detection of which leads to a precise diagnosis.¹ Among soft tissue sarcomas, these specific chromosomal translocations include the t(X;18)(p11;q11) for synovial sarcoma, t(11;22)(q24;q12) or t(21;22)(q22;q12) for Ewing tumor family (ES-PNET), and t(2;13)(q35;q14) or t(1;13)(p36;q14) for alveolar rhabdomyosarcomas. Molecular diagnostic tests have contributed immensely to accurate and specific diagnosis of soft tissue sarcomas,^{1,2} in part due to the limited utility of immunohistochemical stains.³ Synovial sarcoma (SS) is an aggressive sarcoma with a propensity for late local recurrence and metastasis. After rhabdomyosarcoma, SS is the second most common soft tissue sarcoma in children and adolescents. SS accounts for between five and 10 percent of all soft tissue sarcomas and most commonly occurs as a deep-seated tumor within the upper and

lower extremities of older children and young adults.⁴ SS can display a variable degree of epithelial differentiation with a biphasic or monophasic pattern histologically. Greater than 90 percent of SS cases harbor a specific chromosomal translocation t(X;18)(p11;q11), leading to the

formation of the SS18-SSX fusion gene, which can be identified definitively by molecular methods.^{1,2,5,6}

We present a case of a 16-year-old female with a poorly differentiated synovial sarcoma, where the diagnosis was established by molecular diagnostic techniques, including




Fig. 1. Fine needle aspiration air-dried smear of right inguinal mass, showing dispersed monomorphic cells with scant cytoplasm, round nuclei with condensed chromatin, and inconspicuous nucleoli, consistent with small round blue cell tumor. Quik-Dip stain from Mercedes Medical, 1000× original magnification.

reverse transcriptase polymerase chain reaction (RT-PCR) for detecting the *SS18-SSX2* fusion transcript, and fluorescence in situ hybridization (FISH) for demonstrating the absence of *EWSR1* gene rearrangement.

Case. A 16-year-old Hispanic female presented with a one-month history of proximal right thigh pain. Ultrasound showed a deep vein thrombosis in the right common femoral vein and a large complex mass in the right groin. Magnetic resonance imaging revealed an enhancing $9.3 \times 8.9 \times 7.2$ cm mass of the right inguinal region, involving the adductor longus and adductor brevis musculature, with central necrosis. A $7.3 \times 5.4 \times 4.8$ cm peripherally enhancing necrotic right common iliac lymph node was present, with no evidence of metastatic disease.

A CT-guided fine needle aspiration and core needle biopsy of the right inguinal mass demonstrated monotonous, overlapping, hyperchromatic ovoid spindle cell nuclei consistent with malignant small round blue cell tumor (Fig. 1, page 1). The core biopsy showed loosely

cohesive groups of round-to-spindled cells with extensive necrosis (40 percent) within a fibrous background (Fig. 2). Tumor cells stained moderately for CD99, strongly for vimentin, with no staining for desmin, muscle specific actin, S100, CAM 5.2, or epithelial membrane antigen. Based on the histologic features and immunohistochemical staining, the differential diagnosis included extra-skeletal Ewing's sarcoma and SS. Formalin-fixed, paraffin-embedded tumor tissue blocks were sent to Mayo Clinical Laboratories for RT-PCR and FISH studies, which were performed using previously described methods.^{7,8} The *SS18-SSX2* fusion transcript, characteristic of SS, was detected by RT-PCR (Fig. 3, page 3). FISH showed absence of *EWSR1* gene rearrangement, excluding Ewing's sarcoma. The patient was given neoadjuvant chemoradiation therapy as per Children's Oncology Group protocol ARST0332. A right external hemipelvectomy was performed, showing 94 percent tumor necrosis in the main tumor and 100 percent necrosis in the metastatic

lymph node. At 17 months post therapy, the patient has no evidence of tumor recurrence.

Discussion. In this case, the histologic and cytomorphologic appearance of poorly differentiated SS closely resembled other sarcomas, in particular ES-PNET and rhabdomyosarcoma. By immunohistochemistry, negativity for the muscle specific markers excluded rhabdomyosarcoma. Ewing's sarcoma could not be excluded, however, since CD99 and keratin can be expressed in both Ewing's and SS.^{3,5}

While most pediatric sarcomas may require a combination of neoadjuvant chemotherapy, radiation, surgery, and long-term follow-up, the specific protocols may differ depending on the type of sarcoma.⁹ Therefore, precise diagnosis, achieved by molecular or cytogenetic methods, is critical. The SS tumor-specific $t(X;18)(p11;q11)$ translocation can be identified by conventional cytogenetic karyotypic analysis.¹⁰ While a cytogenetic analysis provides a global analysis of all chromosomes and can detect any additional secondary cytogenetic abnormalities, it requires a 1- to 2-cm³-sized fresh, viable, non-necrotic tumor sample, which is possible to obtain only from resection specimens and is not feasible from small needle core biopsies, as in this case. For formalin-fixed, paraffin-embedded tissues, a molecular cytogenetic assay such as FISH or a molecular method such as RT-PCR may be used to identify specific fusion genes or the fusion transcript, respectively.^{11,12} Both FISH and RT-PCR are designed to detect only a specific molecular genetic abnormality, without examining the remainder of the genome (complete chromosomes) in the analyzed tissues.

To identify gene fusions, FISH is performed using locus-specific probes, which are gene-specific complementary sequences of DNA




Fig. 2. Core needle biopsy of right inguinal mass, showing hypercellular sheet of monomorphous cells with hyperchromatic round nuclei, indistinct or absent nucleoli, and scant cytoplasm, within a loose, fibrous stroma, consistent with small round blue cell tumor. H&E stain, 400× original magnification.




Fig. 3. Gel electrophoresis following reverse transcriptase polymerase chain reaction showing the *absence* of the 151 bp band in the patient lane designated P1 in the left one-third of the image, and the *presence* of a 109 bp band in the lane designated P1 in the mid-third of the image, in the presence of appropriate positive and negative controls (lanes designated “pos” and “neg” respectively), with amplification of the reference *PGK1* gene (right one-third of the image), confirming the presence of the *SS18-SSX2* fusion transcript in the analyzed tissue.

that hybridize with the specific gene targets in the analyzed tissue.^{8,13} The translocation in SS involves the *SS18* gene on chromosome 18 and one of several genes (usually *SSX1* or *SSX2* and, much less commonly, *SSX4*) on the X chromosome and results in formation of the *SS18-SSX* oncogenes.^{1,2,4} RT-PCR is a rapid, highly specific, and sensitive technique requiring extraction of tumor RNA, preferably from snap-frozen tissue to yield better RNA integrity, followed by reverse transcription to DNA, and finally PCR for DNA amplification utilizing primers flanking the chimeric gene to be detected.^{6,7} In fixed tissues, RNA integrity depends on the fixative and the time interval between the surgery and the tissue fixation, thus requiring an assay control (housekeeping gene to be amplified). In our case, primers specific for *SS18* and *SSX* were used, and the amplified product was analyzed via electrophoresis and compared with appropriate positive and negative controls (Fig. 3).⁷ **Table 1** (page 4) shows a comparison of RT-PCR and FISH assays in detecting the *SS18-SSX* fusion transcripts in SS.

Approximately two-thirds of SS cases have the *SS18-SSX1* fusion, and one-third carry the *SS18-SSX2*

fusion. Most biphasic SS have the *SS18-SSX1*, and monophasic tumors may have either fusion. Earlier studies showed significantly improved prognosis with the *SS18-SSX2* fusion; however, more recent studies have shown that the *SS18-SSX* fusion type is not a significant factor in prognosis.^{4,14}

To summarize, the use of RT-PCR and FISH assays for the detection of the *SS18-SSX* fusion is the gold standard for the diagnosis of SS. These assays can be used with limited available tissue, as with fine needle core biopsies, and can be applied to formalin-fixed, paraffin-embedded tissues, in contrast to cytogenetic analysis that requires fresh, viable tissue. □

Acknowledgement

The authors would like to thank André M. Oliveira, MD, PhD, of Mayo Clinic, Rochester, Minn., for kindly providing the image for the RT-PCR assay and the FISH and RT-PCR procedural references.

1. Antonescu CR. The role of genetic testing in soft tissue sarcoma. *Histopathology*. 2006;48(1):13–21.
2. Smith SM, Coleman J, Bridge JA, Iwenofu OH. Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors. *J Surg Oncol*. 2015;111(5):520–531.
3. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral

nerve sheath tumor, and Ewing sarcoma. *Mod Pathol*. 2006;19(5):659–668.

4. Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. *Ann Diagn Pathol*. 2014;18(6):369–380.
5. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon, France: WHO Press; 2013.
6. Tsuji S, Hisaoka M, Morimitsu Y, et al. Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. *Am J Pathol*. 1998;153(6):1807–1812.
7. Jin L, Majerus J, Oliveira A, et al. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and RT-PCR. *Diagn Mol Pathol*. 2003;12(4):224–230.
8. VYSIS EWSR1 break apart FISH probe kit. Abbott Molecular website. <https://www.abbottmolecular.com/products/vysis-ewsr1-break-apart-fish-probe-kit.html>. Accessed Jan. 21, 2016.
9. Hawkins DS, Spunt SL, Skapek SX; COG Soft Tissue Sarcoma Committee. Children’s Oncology Group’s 2013 blueprint for research: Soft tissue sarcomas. *Pediatr Blood Cancer*. 2013;60(6):1001–1008.
10. Sandberg AA. Cytogenetics and molecular genetics of bone and soft-tissue tumors. *Am J Med Genet*. 2002;115(3):189–193.
11. Guillou L, Coindre J, Gallagher G, et al. Detection of the synovial sarcoma translocation t(X;18)(SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: A reliable and powerful diagnostic tool for pathologists. *Hum Pathol*. 2001;32(1):105–112.
12. Ten Heuvel SE, Hoekstra HJ, Suurmeijer AJ. Diagnostic accuracy of FISH and RT-PCR in 50 routinely processed synovial sarcomas. *Appl Immunohistochem Mol Morphol*. 2008;16(3):246–250.
13. Cerrone M, Cantile M, Collina F, et al. Molecular strategies for detecting chromosomal translocations in soft tissue tumors (review). *Int J Mol Med*. 2014;33(6):1379–1391.
14. Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M. Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis. *Springerplus*. 2015;4:375.
15. Szu Hai K, Cleton-Jansen AM, Hogendoorn PC, Bovée JV. Molecular pathology and its diagnostic use in bone tumors. *Cancer Genet*. 2012;205(5):193–204.
16. Amary MF, Berisha F, Bernardi FDC, et al. Detection of SS18-SSX fusion transcripts in

formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. *Mod Pathol.* 2007;20(4):482–496.

Dr. Washburn is a PGY 2 resident in anatomic and clinical pathology, Dr. Fraunhoffer is a professor of pathology

and orthopedics and unit director of bone and soft tissue pathology, and Dr. Kansal is an associate professor of pathology and medical director of the diagnostic molecular laboratory—all in the Department of Pathology and Laboratory Medicine at Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pa.

Table 1. Comparison of RT-PCR and FISH in detecting SS18-SSX fusion transcript in synovial sarcoma

Assay characteristics	Reverse transcriptase polymerase chain reaction	Fluorescence in situ hybridization
Type of assay	RNA-based	DNA-based
Targeted abnormality detected by the assay	Yes	Yes
Applicable tissues	Fresh, snap frozen, and formalin-fixed, paraffin-embedded; snap frozen better than fixed tissues for RNA integrity	Fresh, frozen, and formalin-fixed, paraffin-embedded (interphase or metaphase cell preparations)
Can localize abnormality in specific cells	No	Yes
Requires fluorescence microscope	No	Yes
Applicable for decalcified tissues (formic acid)	No ¹⁵	No ¹⁵
Rate of test failure due to poor RNA quality in formalin-fixed tissues	11.6% ¹¹	Not applicable
Analytical sensitivity	Very high (1 in 10 ⁵ cells), greater than FISH if RNA integrity is not a limiting factor	1 in 10 ³ cells
Fusion transcripts detected	<i>SS18-SSX1</i> , <i>SS18-SSX2</i> ² Provides greater detail (specific RNA transcript) for the fusion as compared with FISH	<i>SS18-SSX1</i> , <i>SS18-SSX2</i> , and <i>SS18-SSX4</i> ²
Limitations	Primer sets may not detect unusual molecular variant transcript	Hybridization signal may be suboptimal, leading to difficult interpretation
Advantages	Due to very high sensitivity, can be used for minimal residual disease or early relapse detection	Can localize abnormality within specific cells
Turnaround time	Rapid	Rapid
Clinical sensitivity (formalin-fixed, paraffin-embedded tissues)	94% ^{6,12} –96% ^{11,13}	82% ¹² –86% ¹⁶
Clinical specificity (formalin-fixed, paraffin-embedded tissues)	100% ^{11,13}	100% ¹²



Test yourself

Here are three questions taken from the case report. Answers are online now at www.amp.org/casereviews and will be published next month in CAP TODAY.

1. Which of the following statements regarding synovial sarcoma is *not* correct?

- Greater than 90 percent of cases of synovial sarcoma have the t(x;18) (p11;q11) translocation.
- Most biphasic synovial sarcomas have the *SS18-SSX1* fusion transcript.
- Most monophasic synovial sarcomas have rearrangement of the *EWSR1* gene region.
- Synovial sarcoma is the second most common soft tissue sarcoma in children after rhabdomyosarcoma.

2. Which of the following statements regarding molecular diagnostic testing is *not* correct?

- Both RT-PCR and FISH provide a global analysis of all chromosomes.
- Cytogenetic karyotypic analysis requires a 1- and 2-cm³-sized fresh, non-necrotic tumor sample.
- Both RT-PCR and FISH may be performed on formalin-fixed, paraffin-embedded tissue samples.
- RT-PCR is best performed on fresh or snap-frozen tissue to ensure RNA integrity.
- Both FISH and RT-PCR are designed only to detect specific molecular genetic abnormalities without examining the remainder of the genome.

3. Recent studies regarding the prognostic significance of *SS18-SSX* fusion type have shown:

- SS18-SSX* fusion type is *not* a significant factor in prognosis.
- SS18-SSX2* fusion is associated with a significantly worse prognosis.
- SS18-SSX1* fusion is associated with a significantly improved overall prognosis.
- SS18-SSX1* fusion is associated with a significantly worse prognosis.